23 results about "Controlled Release Tablet" patented technology

The present invention relates to a multiple controlled-release tablet composition of ruxolitinib or a pharmaceutically acceptable salt thereof, which is useful for treating Janus kinase-associated diseases such as myeloproliferative disorders, and a method for producing the same. More specifically, the present invention relates to a multiple controlled-release tablet composition and a method for producing the same, which exhibits a maximum drug blood concentration similar to that of commercially available immediate-release formulations, while controlling the drug release rate so as to efficiently maintain the drug at or above the effective blood concentration in the body, thereby enabling once-daily administration, unlike commercially available formulations that are administered twice daily.

This invention provides a continuous coating apparatus for sustained-release tablets. The apparatus comprises a die-forming mechanism, a feeding mechanism, a heat-sealing mechanism, a punching mechanism, a shifting mechanism, and a perforation mechanism, all mounted on a frame along the coating conveying direction. The die-forming mechanism forms pores on the lower coating layer to accommodate the sustained-release tablets. The feeding mechanism lays each sustained-release tablet flat into its corresponding pore. The heat-sealing, punching, and perforation mechanisms are respectively used to seal the sustained-release tablets using the upper and lower coating layers, punch holes in the sealed tablets, and cut them from the coating layer. The perforation mechanism employs a stamping structure, with a centering mechanism and a trimming mechanism arranged from top to bottom along the stamping direction. The centering mechanism gathers the sustained-release tablets in the coating layer into the pores in the lower die, and the trimming mechanism trims the punched tablets. The shifting mechanism employs an intermittent motion structure, enabling the upper and lower coating layers to move together along the coating conveying direction.

The present disclosure relates to a controlled-release, tablet composition and a process for its preparation. The composition, in the form of compressed effervescent tablets, is designed to deliver active agents across a wide pH range. The composition has enhanced stability against degradation and improved delivery performance. The compositions are useful in various fields such as personal skincare, household cleansers, workplace cleansers, odour control applications and the like. The composition also includes features that enable tracking of the environmental impact associated with product usage. The process for the preparation of the composition in accordance with the present disclosure is simple, economic and environment friendly.

The application provides a tivozanib hydrochloride osmotic pump controlled-release tablet, which is characterized in that the tablet comprises a tablet core, and the tablet core comprises 100 parts of tivozanib hydrochloride, 30-60 parts of a retarder, 40-80 parts of a disintegrant and / or an osmotic pressure promoter, 40-90 parts of a cosolvent and 8-15 parts of a pore-forming agent in terms of weight fraction. The tivozanib hydrochloride osmotic pump controlled-release tablet can realize zero-order release and has a 24-hour cumulative release degree of more than 96%, so that the bioavailability of tivozanib in vivo is improved, and the frequency or dosage of oral solid preparations of tivozanib is reduced.

The utility model relates to a granulator for producing nifedipine controlled release tablets, which aims to solve the technical problems that the maintenance cost is increased and the production continuity is reduced because equipment needs to be opened or parts need to be disassembled when a cutter is cleaned or materials are discharged, and the operation is complicated and time-consuming, and comprises a partition plate, a transmission rod and a material barrel, the transmission rod vertically penetrates through the center of the bottom of the centrifugal screen drum and is fixedly connected with the centrifugal screen drum, an insertion opening is formed in one side of the bottom of the centrifugal screen drum, an insertion plate is movably inserted into the inner side of the insertion opening, and a bottom frame is fixedly connected to the bottom, under the insertion plate, of the centrifugal screen drum; a connecting rod is fixedly connected to the surface of the top end of the inserting plate, a cutter is fixedly connected to the top end of the connecting rod, and two cleaning plates are fixedly connected to the side wall of the transmission rod below the cutter. Discharging is facilitated by arranging the pushing ring and the scraping plate, so that the device does not need to be disassembled, and the device is convenient, rapid and high in efficiency.

The invention discloses a preparation method of a theophylline controlled-release tablet and the theophylline controlled-release tablet. The preparation method comprises the following steps: S1, dry granulation of a medicine layer: preparing medicine layer particles from theophylline, a slow-release hydrophilic polymer material, a moisture absorbent, a flow aid and a lubricant; s2, performing dry granulation on the boosting layer: preparing boosting layer particles from a coloring material, an expansive high polymer material, a moisture absorbent, a flow aid and a lubricant; s3, tabletting of double-layer tablets: adding the medicine layer particles and the boosting layer particles into a double-layer tablet press for tabletting; s4, semi-permeable membrane coating: adding the theophylline double-layer tablet chip and a semi-permeable membrane coating solution into a coating machine; and S5, laser drilling: drilling holes in the theophylline double-layer semi-permeable membrane coating tablets through a laser drilling machine. The osmotic pump controlled release technology is utilized to control the constant-speed release of the medicine, the medicine effect is more lasting, the plasma concentration is stable, the adverse reaction of the medicine is effectively reduced, the medicine taking frequency is reduced, the medicine taking compliance of a patient is improved, and the clinical treatment effect of the medicine is improved.

An ibuprofen controlled-release tablet and a method for preparing same are provided. The controlled-release tablet includes a drug-containing immediate-release layer and a drug-containing sustained-release layer, where a mass of ibuprofen in the drug-containing sustained-release layer is greater than a mass of ibuprofen in the drug-containing immediate-release layer, and a ratio of the mass of the ibuprofen in the drug-containing sustained-release layer to the mass of the ibuprofen in the drug-containing immediate-release layer is ≤7. The tablet has an effective analgesic effect for 24 h after administration.

1. The name of the design product: packaging box (nifedipine controlled release tablets). 2. The use of the design product: the design product is used for the packaging of medicines. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view.

The present application relates to a kind of poorly soluble drug osmotic pump controlled-release tablets and its preparation method, the osmotic pump controlled-release tablets include tablet core, semi-permeable membrane coating and release hole, the tablet core includes solid dispersion of poorly soluble drug and penetration agent, the solid dispersion of poorly soluble drug includes poorly soluble drug and carrier, the poorly soluble drug is selected from nicardipine, nifedipine, felodipine and their pharmaceutically acceptable salt, the carrier is selected from organic acid substance.Compared with prior art, the poorly soluble drug osmotic pump controlled-release tablets of the present application greatly improves the drug solubility, without using a large amount of penetration agent or other excipients in tablet core, drug loading is increased, and tablet core will not be too large;In vivo release greatly improves;Preparation process is simple, equipment requirement and cost are low, and easy to industrialization.

The present invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a loxoprofen sodium controlled-release tablet, and a preparation method and use thereof. The controlled-release tablet includes a drug-containing immediate-release layer, a drug-containing tablet core layer and a drug-containing sustained-release layer. The drug-containing tablet core layer includes a plain tablet core, an enteric coating film and an isolation coating film. The preparation method includes: preparing a granule of a drug-containing immediate-release layer and a granule of drug-containing sustained-release layer respectively from a raw material of the drug-containing immediate-release layer and a raw material of the drug-containing sustained-release layer; subjecting a raw material of a plain tablet core to wet granulation, tableting, and then sequentially coating with a first layer of isolation coating , a second layer of enteric coating, and a third layer of isolation coating to obtain a drug-containing tablet core; and placing the drug-containing tablet core on the granule of the drug-containing sustained-release layer, pre-compressing, and then placing the granule of the drug-containing immediate-release layer on the pre-compressed tablet, tableting, and coating to obtain the tablet. In the present invention, the tablet structure, raw materials, coating and the like components of the core-coated tablet are designed to achieve the effect of sustained-release of the loxoprofen sodium tablet core, so that the tablet can be effective in vivo for 12 h and improve patient compliance.

The present application provides a kind of felodipine osmotic pump controlled-release tablets and preparation method thereof, the osmotic pump controlled-release tablet is composed of osmotic pump controlled-release tablet core and water-insoluble coating layer (single side laser punching), the weight percentage of the felodipine osmotic pump controlled-release tablet contains immediate-release coating layer, controlled-release coating layer, propelling coating layer, water-insoluble coating layer is (5~20) :(5~30) :(10~50) :(5~30).The present application also provides a kind of preparation method of felodipine osmotic pump controlled-release tablet and its application in treating hypertension.The formulation of the felodipine osmotic pump controlled-release tablet of the present application is reasonable, and production process is simple and easy to control;By replacing traditional controlled-release tablet polyethylene oxide with different povidone, the controllability of felodipine osmotic pump controlled-release tablet preparation is significantly improved, and the difficulty of cleaning in production is reduced.

The invention provides a controlled release tablet and a preparation method thereof. The controlled release tablet comprises a tablet core and a coating wrapping the tablet core, the tablet core comprises a drug-containing layer and a boosting layer compounded on the drug-containing layer, the coating is provided with drug release holes on one side of the drug-containing layer, and the coating is a semi-permeable film; the raw materials of the medicine-containing layer comprise raw material medicines and auxiliary materials; in the medicine-containing layer, the weight of the raw material medicine is 25.0-50.0 wt% of the weight of the medicine-containing layer; in the drug-containing layer, the raw materials of the auxiliary materials comprise one or more of poloxamer, lauryl sodium sulfate, polyoxyl stearate and vitamin E polyethylene glycol succinate, and the weight of the components accounts for 0.0-10.0 wt% of the weight of the drug-containing layer. The proportion of the controlled release tablet API in the drug-containing layer is larger than or equal to 25 wt%, the weight and size of the controlled release tablet are reduced, the small-size controlled release tablet can be prepared, the swallowing compliance of a patient is improved, and the risk of intestinal obstruction in vivo is reduced.

1. The name of the design product: packing box (nifedipine controlled release tablet). 2. The use of the design product: for product packing. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo best indicating the design points: perspective view 1.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a paliperidone long-acting oral suspension based on ion exchange resin and a preparation method of the paliperidone long-acting oral suspension. The cation exchange resin and the paliperidone are adopted to form a medicine-resin compound, pH responsive release is achieved through ionic bonds, and the effects of low dissociation in gastric juice and slow release in intestinal juice are achieved; meanwhile, a ready-to-use oral suspension is developed for patients with dysphagia, a flavoring agent is added, the taste is improved, compared with controlled release tablets, the compliance of the patients can be improved, the medication convenience can be improved, and the paliperidone long-acting oral suspension preparation has a good application prospect.

Disclosed in the present invention are a topiroxostat osmotic pump tablet and a preparation method therefor. The topiroxostat osmotic pump tablet comprises: a tablet core consisting of a drug layer and a push layer; a semipermeable membrane coating outside the tablet core; a single drug-release orifice on the controlled-release tablet surface on the side of the drug layer; and an isolation film coating. Compared with topiroxostat tablets currently on the market, the topiroxostat osmotic pump controlled-release tablet prepared in the present invention achieves sustained and stable constant-rate drug release. The drug in a drug-release layer is not released immediately after a patient takes the drug; within the ten or more hours thereafter, the tablet can release the drug rhythmically under the action of the push layer, maintaining a steady-state plasma concentration, delaying the time at which the peak is reached, and prolonging the half-life of the drug, thereby improving bioavailability and achieving a sustained release effect of 12 h or more. Because a dual-layer osmotic pump controlled-release technology is used, the drug has stronger controllability, a more complete release, and higher bioavailability in comparison with single-layer tablets.

The invention relates to an osmotic pump type controlled release tablet preparation as well as a preparation method and application thereof. The osmotic pump type controlled release tablet preparation is a double-layer controlled release tablet and comprises a double-layer tablet core and a semi-permeable membrane coating, the double-layer tablet core comprises a medicine carrying layer and a pushing layer, and at least one channel hole is formed in the side, close to the medicine carrying layer, of the semi-permeable membrane coating and connected with the medicine carrying layer and the outside, so that medicine can be released. The osmotic pump type controlled release tablet disclosed by the invention has a curative effect consistent with that of a commercially available product, is more suitable for being produced by domestic pharmaceutical production enterprises, has lower production cost, and is small in batch-to-batch difference in dissolution speed and safe in medication.

This invention belongs to the field of pharmaceutical preparation technology, and particularly relates to ketorolac tromethamine biphasic controlled-release tablets and their preparation method. The ketorolac tromethamine biphasic controlled-release tablets include a controlled-release layer and an immediate-release layer. The controlled-release layer includes a double-layer tablet core containing a drug-containing layer and a semi-permeable membrane disposed outside the double-layer tablet core. The semi-permeable membrane allows water molecules to pass through, and has release pores on its side facing the drug-containing layer. After the double-layer tablet core absorbs water molecules passing through the semi-permeable membrane, the ketorolac tromethamine containing the drug-containing layer is released. The immediate-release layer includes a therapeutically effective amount of ketorolac tromethamine and pharmaceutically acceptable immediate-release excipients. This invention combines the effects of immediate release and zero-order release with controlled release, achieving both rapid and long-lasting drug action. It can continuously and stably release the drug within 24 hours, which is beneficial for maintaining a stable blood drug concentration in patients during medication, reducing the frequency of dosing to once daily, and providing a safer, more stable, and longer-lasting analgesic drug formulation for clinical use.

The invention provides a double-layer tablet and a preparation method thereof. The double-layer tablet comprises a quick-release layer and a slow-release layer, wherein the quick-release layer comprises an indometacin solid dispersion, a disintegrating agent, a filling agent and a lubricating agent; the sustained-release layer comprises an indometacin solid dispersion, a disintegrating agent, a filling agent, a high-molecular sustained-release polymer and a lubricating agent. The quick-release layer is prepared by adopting a direct powder compression method, and then the raw materials of the slow-release layer are mixed and compressed to the second layer to obtain the double-layer tablet. The preparation process is simple, the medicine is rapidly released to 45% at the initial stage of tablet release, the medicine is continuously and stably released after 20 min, the final release amount reaches 80% or above, no burst release phenomenon exists in the release process, and meanwhile good adhesion time and adhesion force are guaranteed.

The present application provides a controlled release tablet of Brivaracetam and a preparation method thereof, which comprises: a bilayer tablet core containing Brivaracetam, which is composed of a drug-containing layer and a push layer; and a semi-permeable membrane coating with a drug release hole arranged outside the bilayer tablet core, wherein the drug-containing layer contains an effective dose of Brivaracetam, a sustained-release material I, a sustained-release material II, a binder I and other pharmaceutical excipients; the sustained-release material I is carbomer, the sustained-release material II is selected from any one of hydroxypropyl methyl cellulose, polyethylene oxide and polyvinyl pyrrolidone, and the weight ratio of the sustained-release material II to the sustained-release material I is 1:1-5:1; and the push layer contains a hydrophilic polymer, an osmotic pressure regulator, a binder II and other pharmaceutical excipients. The controlled release tablet of Brivaracetam of the present application has a significant zero-order drug release feature, a stable blood drug concentration, a long-lasting drug effect, and a good medication compliance with once-a-day administration.

The invention relates to the technical field of pharmaceutical preparations, in particular to a cilnidipine osmotic pump controlled release tablet and a preparation method thereof. The preparation method of the cilnidipine osmotic pump controlled release tablet comprises the following steps: mixing cilnidipine and a cyclodextrin derivative to obtain a cilnidipine cyclodextrin inclusion compound; mixing the cilnidipine cyclodextrin inclusion compound with an osmotic pressure accelerant, a cosolvent, a disintegrating agent, an adhesive and a diluent, and granulating to obtain cilnidipine cyclodextrin inclusion compound particles; mixing and tabletting the cilnidipine cyclodextrin inclusion compound particles, a flow aid and a lubricant to obtain a cilnidipine osmotic pump controlled release tablet core; and mixing the cilnidipine osmotic pump controlled release tablet core with a pore-foaming agent, an opacifying agent, a plasticizer and a coating material, and carrying out coating treatment to obtain the cilnidipine osmotic pump controlled release tablet. The cilnidipine osmotic pump controlled release tablet prepared by the invention can prolong the action time of the medicine, improve the bioavailability of the medicine, reduce the peak-valley effect of the blood concentration of the medicine and improve the medication compliance of a patient.

This invention discloses an automatically dust-cleaning controlled-release tablet loading tray, belonging to the technical field of loading trays. It includes a rotating platform, a rotating base fixed to the rotating platform, a loading tray dial rotatably mounted on the rotating platform, and a drug placement hole on the dial. A boss housing is mounted on the top of the rotating base. A shaped connecting rod is mounted on the side wall of the boss housing via a movable component. One end of the shaped connecting rod is also mounted on the bottom edge of the boss housing via a connecting rod bracket. A brush is mounted on one bottom side of the shaped connecting rod, corresponding to the drug placement hole. This invention primarily enables automatic dust cleaning of the controlled-release tablet loading tray, eliminating the need for manual cleaning and achieving the goal of cleaning the surface of the loading tray after each use.

The invention relates to the field of pharmaceutical preparations, in particular to a sacubitril and valsartan sodium controlled-release composition, a preparation method and application thereof, and a medicine. The invention provides a double-layer osmotic pump controlled release tablet of sacubitril and valsartan sodium, the tablet can continuously release medicine within 24 hours, and the oral administration of the original developed preparation on the market is changed into the oral administration of the original developed preparation once every two days, so that the medication compliance of a patient is greatly improved. Besides, the drug release of the preparation is characterized by zero-order release, the influence of the pH value of the environment is small, the influence of the complex environment of the gastrointestinal tract in the gastrointestinal tract is small, the safety of the drug is greatly improved, the fluctuation of the blood concentration caused by the peak valley effect of a common quick-release tablet is avoided, the steady-state blood concentration can be achieved after the preparation is taken once, and the preparation is safe and reliable. The effectiveness of the medicine is improved.